HHS Issues New Rules To Open Up Data From Clinical Trials
(By Richard Harris for NPR) Universities and drug companies that use human volunteers for research face tough new rules designed
Read More
Part D/Prescription Drugs
Colombia plans to proceed with price cut on Novartis cancer drug
(By Ed Silverman for STAT) After weeks of deliberations, the Colombia health minister is proceeding with plans to unilaterally lower
Read MoreFDA chastises companies for touting an unapproved opioid painkiller
(By Ed Silverman for STAT) File this under “What were they thinking?” At a time when selling opioid painkillers is
Read MoreDoes access to medical marijuana reduce opioid deaths?
(By Sharon Begley for STAT) When legal medical marijuana dispensaries start operating in a state, deaths from opioid overdoses in
Read MoreLawmakers ask HHS to probe the Medicaid drug rebate program
(By Ed Silverman for STAT) In the wake of the controversy over EpiPen pricing,1 a group of lawmakers is demanding
Read MoreCandidates Decry High Drug Prices, But They Have Few Options For Voters
(By Julie Rovner for Kaiser Health News) In this year’s presidential campaign, health care has taken a back seat. But
Read MoreWATCH: How EpiPens — and epinephrine — stop a serious allergic reaction
(By Ike Swetlitz for STAT) EpiPens. They can quickly deliver a lifesaving dose of the chemical epinephrine to anyone experiencing
Read MoreBipartisan bill in Congress would require drug makers to justify, limit price hikes
(By Ed Silverman for STAT) In response to the intensifying outrage over the cost of medicines, a bipartisan group of
Read MoreFDA panel votes to remove serious warning from Pfizer’s smoking cessation pill
(By Ed Silverman for STAT) Pfizer won a crucial battle in its quest to widen the market for its Chantix
Read MoreAllergan CEO looks smart for pledging to rein in prices. But will it make a difference?
(By Ed Silverman for STAT) How much credit should we give Brent Saunders for trying to put a lid1 on
Read More